Satsuma Pharmaceuticals Inc

NASDAQ:STSA   3:59:50 PM EDT
7.28
-0.67 (-8.43%)
Regulatory, Earnings Announcements

Satsuma Pharmaceuticals Announces Positive Results From The Ongoing STS101 Ascend Phase 3 Open-Label, Long-Term Safety Trial

Published: 09/20/2022 13:26 GMT
Satsuma Pharmaceuticals Inc (STSA) - Satsuma Pharmaceuticals Announces Positive Results From the Ongoing Sts101 Ascend Phase 3 Open-label, Long-term Safety Trial.
Satsuma Pharmaceuticals Announces Positive Results From the Ongoing Sts101 Ascend Phase 3 Open-label, Long-term Safety Trial.
Satsuma Pharmaceuticals Inc - Sts101 Demonstrated a Favorable Safety and Tolerability Profile, Consistent With Clinical Experience to Date.
Satsuma - Subject Exposures Over Time With Sts101mk2 Exceed FDA Requirement to Support Planned NDA Submission in Q1 2023, and Potential Approval.
Satsuma- Subjects Using Sts101mk2 to Treat Migraine Attacks Achieved Freedom From Pain by 2 Hours Post-treatment in 34.2% of Treated Attacks.
Satsuma- Subjects Using Sts101mk2 to Treat Migraine Attacks Achieved Freedom From Mbs by 2 Hours Post-treatment in 53.4% of Treated Attacks.
Satsuma - in Exploratory Post-hoc Analyses, Sts101mk2 Demonstrated Improved Clinical Performance Versus Sts101mk1.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.52

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.46

More details on our Analysts Page.